Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amgen Inc. stock logo
AMGN
Amgen
$462.32
-0.7%
$425.81
$312.39
▼
$483.99
$250.07B0.432.75 million shs1.85 million shs
Novavax, Inc. stock logo
NVAX
Novavax
$8.06
-5.4%
$10.54
$6.20
▼
$13.39
$1.33B2.655.26 million shs4.72 million shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amgen Inc. stock logo
AMGN
Amgen
0.00%+1.14%+7.67%+11.04%+38.29%
Novavax, Inc. stock logo
NVAX
Novavax
0.00%-20.96%-24.33%+5.58%+22.24%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amgen Inc. stock logo
AMGN
Amgen
$462.32
-0.7%
$425.81
$312.39
▼
$483.99
$250.07B0.432.75 million shs1.85 million shs
Novavax, Inc. stock logo
NVAX
Novavax
$8.06
-5.4%
$10.54
$6.20
▼
$13.39
$1.33B2.655.26 million shs4.72 million shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amgen Inc. stock logo
AMGN
Amgen
0.00%+1.14%+7.67%+11.04%+38.29%
Novavax, Inc. stock logo
NVAX
Novavax
0.00%-20.96%-24.33%+5.58%+22.24%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amgen Inc. stock logo
AMGN
Amgen
2.30
Hold$425.69-7.92% Downside
Novavax, Inc. stock logo
NVAX
Novavax
2.20
Hold$12.3353.02% Upside

Current Analyst Ratings Breakdown

Latest AMGN and NVAX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/16/2026
Amgen Inc. stock logo
AMGN
Amgen
Boost Price TargetEqual Weight$400.00 ➝ $430.00
11/12/2026
Amgen Inc. stock logo
AMGN
Amgen
Boost Price TargetBuy$460.00 ➝ $515.00
11/6/2026
Amgen Inc. stock logo
AMGN
Amgen
DowngradeBuy ➝ Hold$450.00 ➝ $470.00
11/6/2026
Novavax, Inc. stock logo
NVAX
Novavax
Reiterated RatingBuy$18.00 ➝ $16.00
11/5/2026
Amgen Inc. stock logo
AMGN
Amgen
Boost Price TargetMarket Perform$395.00 ➝ $464.00
11/5/2026
Amgen Inc. stock logo
AMGN
Amgen
Boost Price TargetNeutral$378.00 ➝ $435.00
11/4/2026
Amgen Inc. stock logo
AMGN
Amgen
Boost Price TargetBuy$452.00 ➝ $531.00
11/4/2026
Amgen Inc. stock logo
AMGN
Amgen
Boost Price TargetMarket Perform$345.00 ➝ $400.00
11/4/2026
Amgen Inc. stock logo
AMGN
Amgen
Boost Price TargetOutperform$430.00 ➝ $470.00
11/4/2026
Amgen Inc. stock logo
AMGN
Amgen
Boost Price TargetHold$384.00 ➝ $440.00
11/4/2026
Amgen Inc. stock logo
AMGN
Amgen
Boost Price TargetEqual Weight$430.00 ➝ $460.00
(Data available from 11/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amgen Inc. stock logo
AMGN
Amgen
$38.90B6.43$33.57 per share13.77$16.08 per share28.75
Novavax, Inc. stock logo
NVAX
Novavax
$411.65M3.23$3.32 per share2.43($0.79) per share-10.20
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amgen Inc. stock logo
AMGN
Amgen
$7.71B$17.2426.8218.463.2424.14%114.99%13.47%2/2/2027 (Estimated)
Novavax, Inc. stock logo
NVAX
Novavax
$440.30M-$0.46N/AN/AN/A-18.64%-14.82%-7.55%N/A

Latest AMGN and NVAX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/5/2026Q3 2026
Novavax, Inc. stock logo
NVAX
Novavax
-$0.3460-$0.19+$0.1560-$0.19$50.42 million$68.30 million
11/3/2026Q3 2026
Amgen Inc. stock logo
AMGN
Amgen
$5.79$6.45+$0.66$7.08$10.07 billion$10.37 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Amgen Inc. stock logo
AMGN
Amgen
$10.082.18%+8.27%58.47%14 Years
Novavax, Inc. stock logo
NVAX
Novavax
N/AN/AN/AN/AN/A

Latest AMGN and NVAX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
10/27/2026
Amgen Inc. stock logo
AMGN
Amgen
quarterly$2.522.25%11/20/202611/20/202612/11/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amgen Inc. stock logo
AMGN
Amgen
3.60
1.48
1.20
Novavax, Inc. stock logo
NVAX
Novavax
N/A
2.15
2.09

Institutional Ownership

CompanyInstitutional Ownership
Amgen Inc. stock logo
AMGN
Amgen
76.50%
Novavax, Inc. stock logo
NVAX
Novavax
53.04%

Insider Ownership

CompanyInsider Ownership
Amgen Inc. stock logo
AMGN
Amgen
0.85%
Novavax, Inc. stock logo
NVAX
Novavax
1.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Amgen Inc. stock logo
AMGN
Amgen
31,500540.91 million536.31 millionOptionable
Novavax, Inc. stock logo
NVAX
Novavax
749165.01 million162.37 millionOptionable

Recent News About These Companies

Novavax (NASDAQ:NVAX) Shares Down 9.4% - What's Next?
Novavax (NVAX) stock trades up, here is why
Novavax (NASDAQ:NVAX) Upgraded at Wall Street Zen
Novavax Earnings Call Signals Stronger Growth Ahead
Novavax Q3 Earnings Call Highlights
Novavax pushes profitability target to 2029, shares dip

New MarketBeat Followers Over Time

Media Sentiment Over Time

Amgen stock logo

Amgen NASDAQ:AMGN

$462.32 -3.35 (-0.72%)
Closing price 04:00 PM Eastern
Extended Trading
$463.64 +1.32 (+0.28%)
As of 07:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Novavax stock logo

Novavax NASDAQ:NVAX

$8.06 -0.46 (-5.40%)
Closing price 04:00 PM Eastern
Extended Trading
$8.09 +0.03 (+0.32%)
As of 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.